Management of Malignant Pleural Effusions and Malignancy-Related Ascites

James Jeffries; Matthew Gayed; Thuong G. Van Ha; Rakesh Navuluri

doi:10.1055/s-0040-1715885

Seminars in Interventional Radiology, Inhaltsverzeichnis

Semin intervent Radiol 2020; 37(04): 434-440
DOI: 10.1055/s-0040-1715885

Trainee Corner

Management of Malignant Pleural Effusions and Malignancy-Related Ascites

James Jeffries

¹Section of Interventional Radiology, Department of Radiology, The University of Chicago, Chicago, Illinois

,

Matthew Gayed

¹Section of Interventional Radiology, Department of Radiology, The University of Chicago, Chicago, Illinois

,

Thuong G. Van Ha

¹Section of Interventional Radiology, Department of Radiology, The University of Chicago, Chicago, Illinois

,

Rakesh Navuluri

¹Section of Interventional Radiology, Department of Radiology, The University of Chicago, Chicago, Illinois

References
1 Rodrîguez-Panadero F, Borderas Naranjo F, López Mejîas J. Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series. Eur Respir J 1989; 2 (04) 366-369
2 Sahn SA. Malignancy metastatic to the pleura. Clin Chest Med 1998; 19 (02) 351-361
3 Antunes G, Neville E, Duffy J, Ali N. Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58 (Suppl. 02) ii29-ii38
4 Taghizadeh N, Fortin M, Tremblay A. US hospitalizations for malignant pleural effusions: data from the 2012 National Inpatient Sample. Chest 2017; 151 (04) 845-854
5 Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015; 20 (04) 654-659
6 Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 (Suppl. 02) ii32-ii40
7 Clive AO, Kahan BC, Hooper CE. , et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014; 69 (12) 1098-1104
8 McCracken DJ, Porcel JM, Rahman NM. Malignant pleural effusions: management options. Semin Respir Crit Care Med 2018; 39 (06) 704-712
9 Ferreiro L, Suárez-Antelo J, Valdés L. Pleural procedures in the management of malignant effusions. Ann Thorac Med 2017; 12 (01) 3-10
10 Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016; (05) CD010529
11 Zarogoulidis K, Zarogoulidis P, Darwiche K. , et al. Malignant pleural effusion and algorithm management. J Thorac Dis 2013; 5 (Suppl. 04) S413-S419
12 Wahidi MM, Reddy C, Yarmus L. , et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial. Am J Respir Crit Care Med 2017; 195 (08) 1050-1057
13 Bhatnagar R, Keenan EK, Morley AJ. , et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med 2018; 378 (14) 1313-1322
14 Ha T, Madoff DC, Li D. Symptomatic fluid drainage: tunneled peritoneal and pleural catheters. Semin Intervent Radiol 2017; 34 (04) 337-342
15 Pollak JS, Burdge CM, Rosenblatt M, Houston JP, Hwu WJ, Murren J. Treatment of malignant pleural effusions with tunneled long-term drainage catheters. J Vasc Interv Radiol 2001; 12 (02) 201-208
16 Davies HE, Mishra EK, Kahan BC. , et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307 (22) 2383-2389
17 Thomas R, Fysh ETH, Smith NA. , et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA 2017; 318 (19) 1903-1912
18 Iyer NP, Reddy CB, Wahidi MM. , et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions. A systematic review and meta-analysis. Ann Am Thorac Soc 2019; 16 (01) 124-131
19 Fysh ETH, Waterer GW, Kendall PA. , et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest 2012; 142 (02) 394-400
20 Freeman RK, Ascioti AJ, Mahidhara RS. A propensity-matched comparison of pleurodesis or tunneled pleural catheter in patients undergoing diagnostic thoracoscopy for malignancy. Ann Thorac Surg 2013; 96: 259-263 , discussion 263–254
21 Hunt BM, Farivar AS, Vallieres E. , et al. Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg 2012; 94: 1053-1057 ; discussion 1057–1059
22 American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162 (05) 1987-2001
23 Feller-Kopman DJ, Reddy CB, DeCamp MM. , et al. Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med 2018; 198 (07) 839-849
24 Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 2003; 15 (02) 59-72
25 Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 2012; 4 (04) 87-95
26 Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330 (05) 337-342
27 Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental observations. Ann Surg 1986; 203 (06) 644-651
28 Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996; 83 (01) 6-14
29 Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18 (05) 945-949
30 Ringenberg QS, Doll DC, Loy TS, Yarbro JW. Malignant ascites of unknown origin. Cancer 1989; 64 (03) 753-755
31 Lacy JH, Wieman TJ, Shively EH. Management of malignant ascites. Surg Gynecol Obstet 1984; 159 (04) 397-412
32 Ammouri L, Prommer EE. Palliative treatment of malignant ascites: profile of catumaxomab. Biologics 2010; 4: 103-110
33 Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manage 1998; 16 (02) 96-101
34 Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529
35 Kellerman PS, Linas SL. Large-volume paracentesis in treatment of ascites. Ann Intern Med 1990; 112 (12) 889-891
36 Stephenson J. The development of clinical guidelines on paracentesis for ascites related to malignancy. Palliat Med 2003; 17 (04) 379-380 , author reply 380
37 Gotlieb WH, Feldman B, Feldman-Moran O. , et al. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer. Gynecol Oncol 1998; 71 (03) 381-385
38 Cruikshank DP, Buchsbaum HJ. Effects of rapid paracentesis. Cardiovascular dynamics and body fluid composition. JAMA 1973; 225 (11) 1361-1362
39 Schumacher DL, Saclarides TJ, Staren ED. Peritoneovenous shunts for palliation of the patient with malignant ascites. Ann Surg Oncol 1994; 1 (05) 378-381
40 Smolle E, Taucher V, Haybaeck J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Res 2014; 34 (04) 1553-1561
41 Ross GJ, Kessler HB, Clair MR, Gatenby RA, Hartz WH, Ross LV. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. AJR Am J Roentgenol 1989; 153 (06) 1309-1311
42 Lungren MP, Kim CY, Stewart JK, Smith TP, Miller MJ. Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients. J Vasc Interv Radiol 2013; 24 (09) 1303-1308
43 Belfort MA, Stevens PJ, DeHaek K, Soeters R, Krige JE. A new approach to the management of malignant ascites; a permanently implanted abdominal drain. Eur J Surg Oncol 1990; 16 (01) 47-53
44 Bui CD, Martin CJ, Currow DC. Case report; effective community palliation of intractable malignant ascites with a permanently implanted abdominal drain. J Palliat Med 1999; 2 (03) 319-321
45 Sabatelli FW, Glassman ML, Kerns SR, Hawkins Jr IF. Permanent indwelling peritoneal access device for the management of malignant ascites. Cardiovasc Intervent Radiol 1994; 17 (05) 292-294
46 Mercadante S, Intravaia G, Ferrera P, Villari P, David F. Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Support Care Cancer 2008; 16 (08) 975-978
47 Qu C, Xing M, Ghodadra A, McCluskey KM, Santos E, Kim HS. The impact of tunneled catheters for ascites and peritoneal carcinomatosis on patient rehospitalizations. Cardiovasc Intervent Radiol 2016; 39: 711-716
48 Perera E, Bhatt S, Dogra VS. Complications of Denver shunt. J Clin Imaging Sci 2011; 1: 6
49 Becker G, Galand D, Blum HE. Malignant ascites: systematic review and guideline for treatment. European Journal of Cancer 2006; 42 (05) 589-597
50 Campbell C. Controlling malignant ascites. Eur J Palliat Care 2001; 8 (05) 187-190